drugset
drugset / Trial / NCT02259764

Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses of KUC 7483 CL Tablets in Healthy Male Volunteers

NCT02259764 ↗

Phase 1 Completed 24 enrolled Boehringer Ingelheim
RandomizedParallel-groupDouble-blindTreatment

Summary

Study to investigate safety, tolerability and pharmacokinetics of KUC 7483 CL

Timeline

Start
2004-08
Primary completion
2004-09
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject KUC 7483 CL Unknown 400 mg Oral
Subject KUC 7483 CL Unknown 440 mg Oral
Subject KUC 7483 CL Unknown 480 mg Oral

Indications

No indication recorded.